UPDATE 1-FDA approves lower dose of Lilly-Incyte arthritis drug
June 01, 2018 at 11:55 AM EDT
June 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.
